A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Part of paid clinical trials in Duarte, California.
- Sponsor
- BeOne Medicines
- Study ID
- NCT07277231
- Phase
- PHASE3
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Sonrotoclax — DRUGAdministered orally.
- Zanubrutinib — DRUGAdministered orally.
- Acalabrutinib — DRUGAdministered orally.
- Venetoclax — DRUGAdministered orally.
Study Details
The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic leukemia (CLL).
Key Dates
- First listed
- Dec 11, 2025
- Start date
- Jan 22, 2026
- Status verified
- Aug 2026
- Primary completion
- Feb 28, 2031
- Completion
- Nov 30, 2031
Study Design
- Enrollment
- 500 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm A: Sonrotoclax plus ZanubrutinibParticipants will receive sonrotoclax and zanubrutinib for a fixed duration followed by observation.
- Active Comparator: Arm B: Venetoclax plus AcalabrutinibParticipants will receive venetoclax and acalabrutinib for a fixed duration followed by observation.
Primary Outcome Measure
Progression-Free Survival (PFS) as Determined by Independent Review Committee (IRC) [ Time Frame: Up to approximately 70 months ]
Central Contacts
- Study Director8778285568
Locations (13)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| City of Hope National Medical Center | Duarte | California | 91010-3012 | - |
| Chao Family Comprehensive Cancer Center | Orange | California | 92868-3201 | - |
| Stanford Cancer Institute | Palo Alto | California | 94304-2205 | - |
| Rocky Mountain Cancer Centers (Williams) Usor | Aurora | Colorado | 80012-5405 | - |
| Mount Sinai Medical Center Braman Comprehensive Cancer Center | Miami | Florida | 33140 | - |
| Northwestern University | Chicago | Illinois | 60611 | - |
| Midwestern Regional Medical Center | Zion | Illinois | 60099-2676 | - |
| Ochsner Clinic Foundation | New Orleans | Louisiana | 70121-2429 | - |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | - |
| Upmc Hillman Cancer Center(Univ of Pittsburgh) | Pittsburgh | Pennsylvania | 15232-1309 | - |
| Texas Oncology Tyler | Tyler | Texas | 75702-7522 | - |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109-4433 | - |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226-3522 | - |
Find similar trials in Duarte, CA
By condition
By specialty
By research site
City of Hope National Medical Center· Duarte, CAChao Family Comprehensive Cancer Center· Orange, CAStanford Cancer Institute· Palo Alto, CARocky Mountain Cancer Centers (Williams) Usor· Aurora, COMount Sinai Medical Center Braman Comprehensive Cancer Center· Miami, FLNorthwestern University· Chicago, IL
Related Studies
- A Long-term Extension Study of PCI-32765 (Ibrutinib)PHASE3 · Recruiting · Janssen Research & Development, LLC · Orange, California
- Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)PHASE1 · Recruiting · Baylor College of Medicine · Houston, Texas
- Long-term Follow-up Study of Patients Receiving CAR-T CellsRecruiting · Medical College of Wisconsin · Milwaukee, Wisconsin
- Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaPHASE2 · Recruiting · Mayo Clinic · Scottsdale, Arizona